^
almost2years
Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study. (ASCO 2022)
The primary endpoint is the PFS Plasma samples will be analyzed for KRAS, NRAS, and BRAF mutations by Idylla ctKRAS and Idylla ctNRAS-BRAF-EGFGR. All samples will be also analyzed by NGS, in order to better evaluate the correlation of tumor heterogeneity with pts’ outcomes.
P3 data • Clinical • Liquid biopsy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type
|
Idylla™ BRAF Mutation Test • Idylla™ ctKRAS Mutation Test
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium
2years
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies. (PubMed, Cancers (Basel))
"We tested plasma samples from the Erbitux Metastatic Colorectal Cancer Strategy (ERMES) phase III trial of FOLFIRI+Cetuximab in first-line treatment of RAS/BRAF wild-type mCRC...These data confirm that the occurrence of RAS/BRAF mutations in mCRC patients receiving anti-EGFR agents is relatively frequent. However, the cfDNA dynamics of RAS mutations in patients treated with anti-EGFR agents plus polychemotherapy are complex and might not be directly associated with resistance to treatment."
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Oncomine™ Pan-Cancer Cell-Free Assay • Idylla™ ctKRAS Mutation Test • Idylla™ ctNRAS-BRAF Mutation Test
|
Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium